Tatsuhiro Harada

Title: Tatsuhiro Harada: Innovator in Monoclonal Antibodies and Therapeutic Solutions

Introduction

Tatsuhiro Harada is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies and therapeutic agents. With a total of three patents to his name, Harada's work has the potential to impact various medical conditions.

Latest Patents

One of Harada's latest patents is titled "Generation, expression and characterization of the humanized K33N monoclonal antibody." This invention provides humanized antibodies that specifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases associated with 9 integrin, including cancer and inflammatory diseases such as rheumatoid arthritis and diabetes. Another notable patent is for "Reverse hydroxamic acid derivatives," which describes derivatives that possess TNF-α converting enzyme (TACE) inhibitory activity. These compounds have a specific structure and are designed to target various biological processes.

Career Highlights

Throughout his career, Tatsuhiro Harada has worked with notable companies, including Kaken Pharmaceutical Company, Ltd. and Gene Techno Science Co., Ltd. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Harada has collaborated with esteemed colleagues such as Akihiko Okuyama and Yoichiro Hoshina. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Tatsuhiro Harada's contributions to the field of biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for innovative therapeutic solutions that can improve patient outcomes.